Mirum Pharmaceuticals Wins FDA Approval for ATEBRIOZ
Foster City, California & Wilmington, Delaware, September 25, 2026 Mirum Pharmaceuticals and Incyte have announced a major regulatory milestone...
AAV Gene Therapy
Advertisement
REGENXBIO Reports Three-Year Data for Surabgene in Retinopathy
Rockville, Maryland, U.S., September 24, 2026 REGENXBIO Inc. has presented three-year clinical data for surabgene lomparvovec in patients with...
PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy Program
Warren, New Jersey, August 12, 2026 PTC Therapeutics announced that it was selected as the winning bidder to acquire...
Lexeo Therapeutics Advances LX2020 with FDA RMAT Designation
NEW YORK, August 5, 2026 Lexeo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Samsung Biologics to Acquire PolyPeptide for CHF 1.46B
INCHEON, South Korea, July 20, 2026 Samsung Biologics has announced a landmark all-cash public tender offer to acquire 100%...
Advertisements
SystImmune Advances Oncology Portfolio with Iza-bren Approval
REDMOND, Wash., July 17, 2026 SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd., has received...
REGENXBIO Reports Positive Long-Term Gene Therapy Results
ROCKVILLE, Md., July 18, 2026 REGENXBIO Inc. has announced positive long-term clinical data for its investigational one-time gene therapy,...
Voyager Shares Positive Six-Month Alzheimer’s Data
LEXINGTON, Mass., July 13, 2026 Voyager Therapeutics presented new six-month good laboratory practice (GLP) toxicology data demonstrating that its...
Opus Genetics Provides BEST1 Phase 1/2 Trial Timeline for OPGx-BEST1 Data
RESEARCH TRIANGLE PARK, N.C., July 9, 2026 Opus Genetics announced an important clinical development update for its Phase 1/2...
Apertura Gene Therapy Advances NPC1 Gene Therapy Research
NEW YORK | July 9, 2026 Apertura Gene Therapy, a biotechnology company developing next-generation adeno-associated virus (AAV) capsids for...
Advertisement
